Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

High IFN-gamma production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4).

Pandiyan P, Hegel JK, Krueger M, Quandt D, Brunner-Weinzierl MC.

J Immunol. 2007 Feb 15;178(4):2132-40.

2.

Cancer statistics, 2007.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.

CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.

PMID:
17237035
3.

Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients.

Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S.

Int Immunol. 2006 Nov;18(11):1591-602. Epub 2006 Sep 20.

PMID:
16987935
4.

Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ.

Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, Komatsu A, Matsubara H, Ochiai T.

Cancer Sci. 2006 Jan;97(1):57-63.

5.

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. Epub 2005 Dec 12.

6.

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ.

Cancer Res. 2005 Nov 15;65(22):10602-12.

7.
8.

Cancer of the ovary.

Cannistra SA.

N Engl J Med. 2004 Dec 9;351(24):2519-29. Review. No abstract available. Erratum in: N Engl J Med. 2005 Jan 6;352(1):104.

PMID:
15590954
9.

The immunobiology of cancer immunosurveillance and immunoediting.

Dunn GP, Old LJ, Schreiber RD.

Immunity. 2004 Aug;21(2):137-48. Review.

10.

Helping the CD8(+) T-cell response.

Bevan MJ.

Nat Rev Immunol. 2004 Aug;4(8):595-602. Review. No abstract available.

PMID:
15286726
11.

Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma.

Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB.

Clin Cancer Res. 2004 Jul 1;10(13):4450-6.

12.

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G.

N Engl J Med. 2003 Jan 16;348(3):203-13.

13.

Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis.

Løvig T, Andersen SN, Thorstensen L, Diep CB, Meling GI, Lothe RA, Rognum TO.

Br J Cancer. 2002 Sep 23;87(7):756-62.

14.

Interleukin-dependent modulation of HLA-DR expression on CD4and CD8 activated T cells.

Salgado FJ, Lojo J, Fernández-Alonso CM, Viñuela J, Cordero OJ, Nogueira M.

Immunol Cell Biol. 2002 Apr;80(2):138-47.

15.
16.

Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.

Schumacher K, Haensch W, Röefzaad C, Schlag PM.

Cancer Res. 2001 May 15;61(10):3932-6.

17.
18.

Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection.

Hoshino Y, Morishima T, Kimura H, Nishikawa K, Tsurumi T, Kuzushima K.

J Immunol. 1999 Nov 15;163(10):5735-40.

19.

CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H.

Cancer Res. 1998 Aug 15;58(16):3491-4.

20.

Supplemental Content

Support Center